

# Exhibit 6

1 Donald G. Norris (SBN 90000)  
2 Douglas F. Galanter (SBN 93740)  
Norris & Galanter LLP  
3 523 W. Sixth St., Suite 716  
Los Angeles, CA 90014  
Tel: 213-232-0855  
4 Fax: 213-286-9499  
dnorris@norgallaw.com  
dgalanter@norgallaw.com

6 William F. Cavanaugh (SBN 133461)  
7 Scott B. Howard (admitted *pro hac vice*)  
William F. Schmedlin (admitted *pro hac vice*)  
8 Patterson Belknap Webb & Tyler LLP  
1133 Avenue of the Americas  
9 New York, NY 10036  
Telephone: (212) 336-2000  
10 Fax: (212) 336-2222  
wcavanaugh@pbwt.com  
sbhoward@pbwt.com  
wschmedlin@pbwt.com

13 Attorneys for Defendants  
14 MEDICIS AESTHETICS, INC., MEDICIS  
PHARMACEUTICAL CORP., VALEANT  
15 PHARMACEUTICALS NORTH AMERICA LLC,  
VALEANT PHARMACEUTICALS INTERNATIONAL,  
and VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

17 **UNITED STATES DISTRICT COURT**  
18 **CENTRAL DISTRICT OF CALIFORNIA**

19 ALLERGAN USA, INC., and  
20 ALLERGAN INDUSTRIE, SAS,

Case No. 8:13-cv-01436 AG (JPRx)

21 Plaintiffs,

22 v.  
**DEFENDANTS' FINAL INVALIDITY**  
**CONTENTIONS**

23 MEDICIS AESTHETICS, INC., MEDICIS  
24 PHARMACEUTICAL CORP., VALEANT  
PHARMACEUTICALS NORTH AMERICA LLC,  
25 VALEANT PHARMACEUTICALS  
INTERNATIONAL, and VALEANT  
PHARMACEUTICALS INTERNATIONAL, INC.

26 Defendants.  
27

28 DEFENDANTS' FINAL INVALIDITY CONTENTIONS  
7681734v.1 Case No. 8:13-cv-01436 AG (JPRx)

1 Medicis Aesthetics, Inc., Medicis Pharmaceutical Corp., Valeant Pharmaceuticals  
2 North America LLC, Valaent Pharmaceuticals International, Valeant Pharmaceuticals International,  
3 Inc., and Galderma Laboratories, L.P. (collectively, "Defendants") by their undersigned attorneys,  
4 submit the following Final Invalidity Contentions ("Invalidity Contentions") with respect to the  
5 asserted claims of U.S. Patent Nos. 8,450,475 ("the '475 patent") and 8,357,795 ("the '795 patent") as  
6 identified in Plaintiffs Allergan Industrie, SAS and Allergan USA, Inc.'s (collectively, "Allergan")  
7 March 7, 2014 First Supplemental Disclosure of Asserted Claims and Infringement Contentions  
8 Pursuant to S.P.R. 2.1 ("Infringement Contentions") and the February 9, 2015 letter from Elizabeth  
9 M. Flanagan identifying the claims Allergan would be asserting.  
10

11 Allergan has identified and asserted the following claims: 1, 2, 4-6, 8-9, 18, and 31-  
12 37 of the '475 patent and claims 1, 3, 8, 11, and 41 of the '795 patent. These Invalidity Contentions  
13 are based in whole or in part on Defendants' present understanding of Allergan's positions as set  
14 forth in its Infringement Contentions, including any underlying interpretations of the claims by  
15 Allergan.  
16

17 Defendants' investigations are ongoing, as is fact discovery. Accordingly,  
18 Defendants reserve the right to expand, add, change or otherwise amend their Invalidity Contentions  
19 consistent with the Federal Rules of Civil Procedure and the Court's rules, based on their continued  
20 investigation, fact discovery, expert discovery, and the Court's claim construction. Defendants also  
21 reserve the right to amend their Invalidity Contentions based on any supplementation by Allergan of  
22 its Infringement Contentions, or of its document production. Defendants also reserve the right to  
23 amend their Invalidity Contentions based on any positions taken by Allergan as to the date of the  
24 alleged invention of the asserted claims.  
25  
26  
27  
28

1                   **DEFENDANTS' FIRST SUPPLEMENTAL INVALIDITY CONTENTIONS**

2                   **I. Identification of Prior Art**

3                   Pursuant to the Court's Standing Patent Rules and in response to Allergan's  
4 Infringement Contentions, Defendants' identify the prior art in the following tables as either  
5 anticipating the asserted claims or rendering them obvious, individually or in combination with each  
6 other and other prior art. To establish the scope and content of the prior art, a motivation to combine  
7 or modify the prior art, or the knowledge and level of skill of those of ordinary skill in the art,  
8 Defendants may also rely on (1) non-prior-art patents, patent applications or publications, or other  
9 evidence (for example, the prosecution history files of U.S. and foreign patent applications) that may  
10 not qualify as prior art under 35 U.S.C. § 102, and (2) statements and admissions made by Allergan  
11 and its employees or agents in the patents-in-suit, during prosecution of the patents-in-suit or related  
12 patent applications, or in other documents.

14                   The prior art references identified below are presumed to be enabled for all that they  
15 disclose. Defendants reserve the right to identify additional prior art evidencing enablement of these  
16 references should Allergan challenge the presumption of enablement. Moreover, Defendants reserve  
17 their right to assert that the claims of the '475 and '795 patents are indefinite under 35 U.S.C. § 112  
18 and are invalid on other statutory bases after the Court issues a ruling on claim construction.

20                   **A. Prior Art Patents and Patent Applications**

22 <b>Patent Number</b>	23 <b>Country of Origin</b>	24 <b>Date of Issue or Publication</b>	25 <b>Abbreviation</b>
WO 96/33751	Int. / FR	Oct. 31, 1996	<i>Debacker</i> <sup>1</sup>

26  
27  
28                   <sup>1</sup> All citations to verified English translation provided herewith

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28	Patent Number	Country of Origin	Date of Issue or Publication	Abbreviation
	5,731,298	US / German	Mar. 24, 1998 (national phase of WO93/12801 (German), filed Dec. 24, 1992)	<i>Reinmuller I</i>
	WO 2005/067944	Int. / German	July 28, 2005	<i>Reinmuller II</i> <sup>2</sup>
	2005/0136122	U.S.	June 23, 2005	<i>Sadozai</i>
	2008/0226724	U.S.	Sep. 18, 2008, earliest priority date Jan. 19, 2007	<i>Ji</i>
	2006/0040894	U.S.	Feb. 23, 2006	<i>Hunter</i>
	WO 2005/112888 A2	Int.	Dec. 1, 2005	<i>Wang</i>
	2006/0194758	U.S.	Aug. 31, 2006	<i>Lebreton</i>
	5,079,236	U.S.	Jan. 7, 1992	<i>Drizen</i>
	6,521,223	U.S.	Feb. 18, 2003	<i>Calias</i>

<sup>2</sup> All citations to English equivalent, U.S. Patent No. 7,902,171

1                   **B. Prior Art Publications**

2 <b>Title</b>	3 <b>Date of Publication</b>	4 <b>Author</b>	5 <b>Publisher/Source</b>	6 <b>Abbreviation</b>
7                   “Effectiveness of 8                   next generation 9                   hyaluronic acid dermal fillers in the treatment of severe nasolabial folds”	10                  Feb. 2007	11                  Lupo <i>et al.</i>	12                  Abstract of a poster 13                  (P2909) presented at the 14                  65 <sup>th</sup> Annual Meeting of the 15                  American Academy of 16                  Dermatology, Feb. 2-6, 17                  2007, in <i>J. Am Acad 18                  Dermatol.</i> , 56(2) Supp 3, 19                  Feb. 2007, p. AB199	20 <i>Lupo</i>
21                  “Volumetry: new 22                  opportunities for 23                  rejuvenating and 24                  modeling of your 25                  facial features”	26                  Sep. / Oct. 27                  2006	28                  Ambroziak, 29                  Marcin	30                  Ekspert, a magazine for 31                  customers clinic in 32                  dermatology and aesthetic 33                  medicine, plastic surgery, 34                  wellness and beauty spa (in 35                  Polish), 36                  September/October 2006 37                  [with verified English 38                  translation] <sup>3</sup>	39 <i>Expert Anti- 40                  Aging</i>
41                  “Juvéderm: A 42                  Hyaluronic Acid 43                  Dermal Filler”	44                  Nov. 2007	45                  Monheit, 46                  Gary D. & 47                  Prather, 48                  Chad L.	49 <i>J Drugs Dermatol.</i> 50                  6(11):1091-5, Nov. 2007	51 <i>Monheit</i>
52                  “Preclinical 53                  evaluation of a 54                  novel hyaluronic 55                  acid 28 mg/ml, 56                  lidocaine 0.3% 57                  stable 58                  combination 59                  product”	60                  Feb. 2007	61                  Toth <i>et al.</i>	62                  Abstract of a poster 63                  (P1039) presented at the 64                  65 <sup>th</sup> Annual Meeting of the 65                  American Academy of 66                  Dermatology, Feb. 2-6, 67                  2007, Washington, DC, in 68 <i>J. Am Acad Dermatol.</i> , 69                  56(2) Supp 3, Feb. 2007, 70                  pAB94	71 <i>Toth</i>

28                  <sup>3</sup> All citations herein to *Expert Anti-Aging* are made with reference to the English translation thereof

Title	Date of Publication	Author	Publisher/Source	Abbreviation
"Influence of various compounds on the degradation of hyaluronic acid by a myeloperoxidase system"	1994	Lindvall, Sven & Rydell, Gunilla	Chemico-Biological Interactions 90: 1-12 (1994)	<i>Lindvall</i>
"Injecting Puragen Plus Into the Nasolabial Folds: Preliminary Observations of FDA Trial"	Nov. 1, 2006	Kinney, Brian M.	Aesthetic Surgery Journal, 26: 741-748 (2006)	<i>Kinney</i>
Summary of Safety and Effectiveness of Cosmetic Tissue Augmentation product (CTA) [Elevesse]	Issued Dec. 20, 2006, Updated Jan. 10, 2007	FDA	Available at <a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=p050033">http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=p050033</a> , accessed Jan 2, 2014	<i>Elevesse Summary</i>

Title	Date of Publication	Author	Publisher/Source	Abbreviation
“Effectiveness and durability of a hyaluronic acid 28 mg/ml, lidocaine 0.3% stable combination product as demonstrated in a multicenter, randomized trial”	Feb. 2007	Hanke <i>et al.</i>	Abstract of a poster (P1040) presented at the 65 <sup>th</sup> Annual Meeting of the American Academy of Dermatology, Feb. 2-6, 2007, Washington, DC, in <i>J. Am Acad Dermatol.</i> , 56(2) Supp 3, Feb. 2007, pAB94	<i>Hanke</i>
“The many ways to cleave hyaluronan”	July 2007	Stern <i>et al.</i>	Biotechnology Advances 25 (2007) 537–557	<i>Stern</i>
“Heat-Induced Generation of Reactive Oxygen Species during Reduction of Dissolved Air Oxygen”	August 2001	Bruskov <i>et al.</i>	Doklady Akademii Nauk, 381 (2): 262-264, 2001	<i>Bruskov</i>
“Degradative Action of Reactive Oxygen Species on Hyaluronan”	Feb. 16, 2006	Šoltés <i>et al.</i>	Biomacromolecules 7:659-668, 2006	<i>Soltés</i>

1	Title	Date of Publication	Author	Publisher/Source	Abbreviation
2	“Stability of Lidocaine in Aqueous Solution: Effect of Temperature, pH, Buffer and Metal Ions on Amide Hydrolysis”	1987	Powell, Michael F.	Pharmaceutical Research, 4 (1): 42-45, 1987	Powell
10	“Thermal Stability of sodium hyaluronate in aqueous solution”	October 1994	Lowry, Karen M. & Beavers, Ellington M.	<i>Journal of Biomedical Materials Research</i> , 28:1239-1244, published 1994	Lowry
14	“Use of hyaluronic acid filleres for the treatment of the aging face”	Sep. 2007	Gold, Michael H.	<i>Clinical Interventions in Aging</i> , 2(3): 369-376 (2007)	Gold

19        **C. Prior Art On Sale in the United States**

20              Defendants identify the dermal fillers Restylane and Perlane, first approved by the  
21 FDA for sale by Q-Med AB in December 2003; Elevers, first approved by the FDA for sale by  
22 Anika Therapeutics in December 2006; Juvederm 24HV and Juvederm 30HV, first approved by the  
23 FDA for sale by Allergan in June of 2006; and Puragen Plus, which was known and used in the US  
24 at least by 2006.  
25  
26  
27  
28

D. Additional Publications

Title	Date of Publication	Author	Publisher/Source	Abbreviation
“Hyaluronic Acid Fillers: A Comprehensive Review”	May 2009	Beasley <i>et al.</i>	<i>Facial Plastic Surgery</i> , 25(2):86-94 (2009)	Beasley
“Comparative Physical Properties of Hyaluronic Acid Dermal Fillers”	Feb. 2009	Kablik <i>et al.</i>	<i>Dermatologic Surgery</i> , 35 Suppl 1:302-12 (2009)	Kablik
“A prospective, split-face, randomized, comparative study of safety and 12-month longevity of three formulations of hyaluronic acid dermal filler for treatment of nasolabial folds”	July 2012	Prager <i>et al.</i>	<i>Dermatologic Surgery</i> , 38(7 Pt 2):1143-50 (2012)	Prager
“Volumizing effects of a smooth, highly cohesive, viscous 20-mg/mL hyaluronic acid volumizing filler: prospective European study”	2009	Hoffman, Klaud	<i>BMC Dermatology</i> , 9:9 (2009)	Hoffman

Title	Date of Publication	Author	Publisher/Source	Abbreviation
"Mentor Corporation Announces FDA Approval of Prevelle Silk"	March 21,2008	Bloomberg News	Bloomberg News, available at <a href="http://www.bloomberg.com/apps/news?pid=newsarchive&amp;sid=arVm09DtA5c">http://www.bloomberg.com/apps/news?pid=newsarchive&amp;sid=arVm09DtA5c</a> , accessed Jan 2, 2014	<i>Prevelle Announcement</i>
Excerpt of FDA Advisory Committee Briefing Document, Juvederm Voluma™ XC	May 2, 2013	Allergan	FDA	<i>Juvederm FDA Briefing</i>

II. **The Prior Art Anticipates or Renders Obvious the Asserted Claims of the '475 and '795 Patents**

Pursuant to the Standing Patent Rules and in response to Allergan's Infringement Contentions, Defendants set forth their contentions as to whether each of the identified items of prior art anticipate each asserted claim of the '475 and '795 patents and/or render the claims obvious. Citations to the prior art references are exemplary; other support for Defendants' Invalidity Contentions may be found elsewhere in the cited references. These charts and citations, at least in part, are based upon the positions taken by Allergan in its Infringement Contentions, without Defendants necessarily adopting the positions reflected therein. The identification of structure or processes in the prior art are not intended to necessarily reflect Defendants' claim interpretations, either directly or by implication.

The citations provided below and in the attached claim charts are representative of the teachings of the listed references. Defendants reserve the right to modify these statements and charts by adding additional prior art references to the extent such modification is appropriate in light of any

1 additional information gained through ongoing investigations or through discovery or in light of  
2 amendments to Allergan's infringement contentions or other arguments made or positions taken by  
3 Allergan.

4       **A. The Asserted Claims of the '475 and '795 Patents are Invalid under 35  
5 U.S.C. § 103**

6              Defendants set forth below and in their claim charts in the attached Exhibits A and B  
7 where each claim limitation of the asserted claims of the '475 patent and the '795 patent may be  
8 found in the disclosed prior art references identified above, rendering the asserted claims obvious.  
9              The claim charts and teachings of each of the listed references may be used in combination with  
10 each other and with other references. Generally, the motivation to combine or modify the prior art  
11 references may be found in the prior art references themselves, either expressly or impliedly, as  
12 filtered through the knowledge of one of ordinary skill in the art; in common sense or common  
13 knowledge; in the knowledge of those of ordinary skill in the art, taking into account the inferences  
14 and creative steps that such a person would employ; in the prior art as a whole; and/or from the  
15 nature of the problem to be solved. Moreover, all prior art identified above in I.A-C is in the same  
16 field of endeavor: dermal fillers. Therefore, such a modification would be a routine arrangement of  
17 known elements in a common field of endeavor, with each element performing the same function it  
18 had been known to perform, yielding no more than what one would expect from such an  
19 arrangement.

20              As disclosed in the '475 patent, HA based soft tissue fillers were known and under  
21 rapid development since the FDA approval of the first HA-based soft tissue filler in December, 2003  
22 ('475 patent, 1:63-65). HA crosslinked with each of four crosslinkers, i.e., 1,4-butanediol diglycidyl  
23 ether (BDDE), divinylsulfone (DVS), 1,2,7,8-diepoxyoctane (DEO) and p-phenylene  
24 bis(ethyl)carbodiimide (BCDI), had been used in approved soft tissue fillers for increased stability  
25 and durability. Uncrosslinked HA had been commonly used together with the crosslinked HA to  
26  
27 and durability. Uncrosslinked HA had been commonly used together with the crosslinked HA to  
28

1 reduce the extrusion force and ease the injection. More specifically, wrinkle fillers containing HA-  
2 BDDE and uncrosslinked HA had been disclosed, such as Juvederm® Ultra (J24HV) and Juvederm®  
3 Ultra Plus (J30HV) (*Lupo*), which contains HA-BDDE and at least 10% uncrosslinked or free HA  
4 (see *Beasley*, Table 1); the two phase filler composition described in Example 2 of *Debacker*, which  
5 contains HA-BDDE and 33% uncrosslinked HA; and the composition disclosed in *Reinmuller II*.  
6 The crosslinked HA can have a mixture of high- and low-molecular weight HA (see *Lebreton*).  
7

8 Pain is a barrier to cosmetic treatment. Lidocaine had been included in various filler  
9 products to reduce the pain. Dermal fillers, such as Puragen® Plus, Elevess® and Prevelle® Silk,  
10 containing lidocaine and HA crosslinked with each of three different crosslinkers, DEO, BCDI and  
11 DVS, respectively, had been approved and reported prior to August 2008 (*Kinney*, *Elevess™*  
12 *Summary*, and *Prevelle® Announcement*). Puragen® Plus and Prevelle® Silk also contain  
13 uncrosslinked HA, i.e., 6% and 2%, respectively. Preclinical and clinical studies had demonstrated  
14 that dermal fillers containing crosslinked HA and lidocaine were stable, effective and durable (see,  
15 e.g., *Toth and Hanke*). Indeed, a heat sterilized injectable gel containing a crosslinked HA and  
16 lidocaine was described in a PCT application filed as early as Dec 24, 1992 (*Reinmuller I*, Example  
17 1).  
18

19 As a medical device to be injected into a human body, an HA filler must be sterile.  
20 Heat sterilization or autoclaving had been used to sterilize almost any type of HA preparations  
21 before 2008, crosslinked and/or uncrosslinked HA, with or without lidocaine (*Drizen*, 7:19-25;  
22 *Lebreton*, Examples 3-4; and *Debacker*, page 14, lines 22-24 and Example 2; *Sadozai*, Example 12;  
23 and *Reinmuller I*, Example 1). Although crosslinked or uncrosslinked HA may be subject to  
24 degradation during autoclaving, the sterilized HA fillers can remain stable for months or even years  
25 (*Drizen*, 7:44-46; *Lowry*, p1244).  
26

27 The prior art reported that lidocaine stabilized HA. For example, *Sadozai*, a prior art  
28 reference disclosed in the priority documents (e.g., U.S. Prov. App. No. 61/085,956 filed Aug. 4,

1 2008, 2:25 to 3:9), but omitted in the ‘475 patent, specifically teaches that “crosslinked HA with  
2 lidocaine can have good biostability, and can in some cases have a synergistic effect, increasing G’  
3 (the storage modulus)” (*Sadozai*, Example 21). This is consistent with the prior art teaching that  
4 adding free radical scavenger to an HA hydrogel decreases viscosity loss due to heat and/or storage  
5 (*Ji*, paras. [0061]-[0064]); lidocaine is a potent hydroxyl radical scavenger and singlet oxygen  
6 quencher (*Das*); and lidocaine was shown to inhibit HA degradation by the mechanism of hydroxyl  
7 radical (*Lindvall*). Moreover, in light of the court’s claim construction ruling, stability requires the  
8 maintenance of only one property, including sterility, and is tied to no particular time frame.  
9

10 More specifically, dermal fillers containing lidocaine and a mixture of HA-BDDE  
11 and at least 10% uncrosslinked HA (such as some Juvederm® products) had been disclosed in  
12 multiple prior art references before August 4, 2008 (see, e.g., *Reinmuller II* and *Hunter*).  
13

14 Accordingly, as of August 4, 2008, the subject matter claimed in the asserted claims  
15 of the ‘475 and ‘795 patents was well known and obvious to a person of ordinary skill in the art..  
16

17 **B. The Asserted Claims of the ‘475 and ‘795 Patents are Invalid under 35  
18 U.S.C. § 102**

19 1. All of the asserted claims are anticipated by *Hunter*, *Sadozai*, and  
20 *Reinmuller II*

21 *Hunter* discusses the many uses of hyaluronic acid, especially when combined with  
22 other molecules. Restylane itself is mentioned by name multiple times. *See, e.g.*, paragraph 0178.  
23 *Hunter* further notes that the composition (one example of which is disclosed to be Restylane) “may  
24 further comprise an anesthetic such as lidocaine[.]” Paragraph 0183. As Restylane-L® is merely the  
25 earlier Restylane compound with the addition of lidocaine, and as Restylane-L® is alleged by  
26 Allergan to infringe all of the asserted claims of the ‘475 patent, then the asserted claims are  
anticipated by *Hunter*.

27 Similarly, *Sadozai* describes a method for composing, stabilizing, and administering a  
28 stabilized hyaluronic acid composition. Within the specification, *Sadozai* specifically references

both Restylane and Perlane as examples when discussing this HA composition. Paragraph 0105. *Sadozai* continues to note the benefits of incorporating lidocaine into such an HA composition, including the benefit of increased stability. Paragraph 0107. Again, as Restylane-L® is merely the earlier Restylane compound with the addition of lidocaine, and as Restylane-L® is alleged by Allergan to infringe all of the asserted claims of the ‘475 patent, then the asserted claims are anticipated by *Sadozai*.

*Reinmuller II* describes hyaluronic acid compositions to be used in the treatment of inflammatory diseases, in particular skin diseases or mucous membrane diseases. The specification of *Reinmuller II* notes that “[h]yaluronic acid is commercially obtainable in the crosslinked state (e.g. ... Restylane from Q-Med). Col. 2, Ins. 21-26. *Reinmuller II* discloses that “[i]n addition to the active compound hyaluronic acid, the pharmaceutical compositions according to the invention can optionally also contain still further pharmaceutical active compounds which are compatible with hyaluronic acid in the course of application, e.g. ... local anesthetics (of the lidocaine or novocaine type). Col. 2, Ins. 54-63. Again, as Restylane-L® is merely the earlier Restylane compound with the addition of lidocaine, and as Restylane-L® is alleged by Allergan to infringe all of the asserted claims of the ‘475 patent, then the asserted claims are anticipated by *Reinmuller II*.

2. Some asserted claims of the '795 Patent are anticipated by *Wang* and the pre-mixing of lidocaine performed by practitioners

Wang teaches processes for preparing injectable HA gels that contain HA-BDDE. Examples 1-7 of Wang are crosslinked HA gels that can include BDDE as a crosslinker. These gels described by Wang are described as usable for “soft tissue augmentation”. *Wang*, 2:1-4. Wang additionally instructs the inclusion of anesthetics, such as lidocaine. *Id.*, 7:3-7. The gel was sterilized via autoclaving. *Id.* at 7:23-24. As a result of these disclosures, Wang anticipates Claims 1, 3, and 8 of the ‘795 Patent.

Additionally, practitioners would pre-mix Restylane and Juvederm products with lidocaine before injecting into their patients. These combinations produced a clinically viable filler that remained sterile. This pre-mixing anticipates Claims 1, 3, and 8 of the '795 Patent.

### **3. Anticipation and Obviousness Charts**

Charts providing more detail on the above-listed anticipation arguments as well as the obviousness arguments for both the '475 and '795 Patents can be found attached.

Dated: February 17, 2015

PATTERSON BELKNAP WEBB & TYLER LLP

By: s/ William F. Cavanaugh, Jr.  
William F. Cavanaugh, Jr.

Attorneys for Defendants  
MEDICIS AESTHETICS, INC., MEDICIS  
PHARMACEUTICAL CORP., VALEANT  
PHARMACEUTICALS NORTH AMERICA LLC,  
VALEANT PHARMACEUTICALS  
INTERNATIONAL,  
and VALEANT PHARMACEUTICALS  
INTERNATIONAL, INC.

1                   **PROOF OF SERVICE**

2                   I am employed in the County of New York, my business address is Patterson Belknap Webb  
3 & Tyler LLP, 1133 Avenue of the Americas, New York, New York 10036. I am over the age of 18  
4 and not a party to the foregoing action.

5                   On February 18, 2015, I caused a copy of the following document(s):

6                   **DEFENDANTS' FINAL INVALIDITY CONTENTIONS**

7 to be served on the interested parties in this action by ELECTRONIC MAIL, via the email addresses  
8 set forth below:

9                   [brooks@fr.com](mailto:brooks@fr.com)  
10                  [countryman@fr.com](mailto:countryman@fr.com)  
11                  [singer@fr.com](mailto:singer@fr.com)  
12                  [kane@fr.com](mailto:kane@fr.com)  
13                  [eflanagan@fr.com](mailto:eflanagan@fr.com)

14                  Juanita R. Brooks  
15                  Fish & Richardson P.C.  
16                  12390 El Camino Real  
17                  San Diego, CA 92130

18                  Craig E. Countryman  
19                  Fish & Richardson P.C.  
20                  555 W. 5<sup>th</sup> Street, 31<sup>st</sup> Floor  
21                  Los Angeles, California 90013

22                  Jonathan E. Singer  
23                  Michael J. Kane  
24                  Fish & Richardson P.C.  
25                  60 South Sixth Street, Suite 3200  
26                  Minneapolis, MN 55402

27                  Elizabeth M. Flanagan  
28                  Fish & Richardson P.C.  
29                  222 Delaware Avenue, 17<sup>th</sup> Floor  
30                  Wilmington, DE 19899

31                  I declare under penalty of perjury that the above is true and correct. Executed on February  
32                  18, 2015, at New York, NY.

33                  \_\_\_\_\_  
34                  /s/ William F. Schmedlin  
35                  William F. Schmedlin